Navigation Links
Anthera Pharmaceuticals Reports 2010 Third Quarter Financial Results and Operational Update
Date:11/2/2010

ovisions of the Private Securities Litigation Reform Act of 1995. These include, but are not limited to, statements relating to the anticipated initiation of Anthera's clinical studies, anticipated duration and expected results of these studies, and the progression of Anthera's products through future stages of clinical development. These forward-looking statements are based on Anthera's expectations as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially as set forth in the Company's public filings with the Securities and Exchange Commission, including Anthera's Quarterly Report on Form 10-Q for the quarter ended June 30, 2010. Anthera disclaims any intent or obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as required by applicable law.

CONTACT: Bianca Nery of Anthera Pharmaceuticals, Inc., bnery@anthera.com or 510-856-5586.ANTHERA PHARMACEUTICALS, INC.A Development Stage CompanySTATEMENT OF OPERATIONS(unaudited)Three Months Ended September 30,Nine Months Ended September 30,2010200920102009OPERATING EXPENSE:  Research and development

$
,885,125$
2,525,948$
8,565,088$
7,727,129  General and administrative

1,510,021884,9084,244,0002,730,482Total operating expense

8,395,1463,410,85622,809,08810,457,611LOSS FROM OPERATIONS:

(8,395,146)(3,410,856)(22,809,088)(10,457,611)OTHER INCOME (EXPENSE):Interest and other income

61,606-76,56221,559Interest and other expense

-(193,556)(4,641,169)(289,776)Total other income (expense)

61,606(193,556)(4,564,607)(268,217)NET LOSS

$  (8,333,540)$   (3,604,412)$  (27,373,695)$   (10,725,828)Net loss per share--basic and diluted

$
(0.36)$
(2.37)$
(1.40)$
(7.16) Weighted-average number of shares used in
per share
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Anthera Announces Third Quarter 2010 Financial Report and Conference Call
2. Anthera Pharmaceuticals Announces Pricing of $31.5 Million PIPE Financing
3. Anthera Pharmaceuticals to Present at Deutsche Bank Securities 35th Annual Health Care Conference
4. Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directors
5. Antheras Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome
6. Following Encouraging Results Anthera to Continue IMPACTS Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
7. Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval
8. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
9. DSMB Supports Continuation of Anthera Phase II Impacts Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
10. Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials
11. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... , March 26, 2015 Even the ... of the Food and Drug Administration,s landmark approval of ... 11 members of Congress calling on the Agency to ... a first-ever medical treatment for women,s most common sexual ... FDA-approved medical treatment options for sexual dysfunction – while ...
(Date:3/26/2015)... and STAEFA, Switzerland , March ... the Venture platform, wirelessly transmits sound from the unaidable ear ... ear. This allows people with single-sided deafness to hear speech ... new fitting process for Phonak CROS II is as easy ... instantly experience the benefits of the CROS solution during the ...
(Date:3/26/2015)... 26, 2015  An Ohio entrepreneur is introducing a product ... As CEO for a start-up company known as SEED ... new business that will empower individuals to manage, review, and ... insecure methods. ... – will enable people to protect their own health records ...
Breaking Medicine Technology:Even The Score Marks 17th Viagra Anniversary with Release of New Letter from Members of Congress to FDA Calling for Equity in Sexual Health 2Even The Score Marks 17th Viagra Anniversary with Release of New Letter from Members of Congress to FDA Calling for Equity in Sexual Health 3Even The Score Marks 17th Viagra Anniversary with Release of New Letter from Members of Congress to FDA Calling for Equity in Sexual Health 4Phonak CROS II: The smart solution for single-sided deafness 2Ohio Entrepreneur Develops Technology that Allows Patients Control Over Their Healthcare Records 2Ohio Entrepreneur Develops Technology that Allows Patients Control Over Their Healthcare Records 3Ohio Entrepreneur Develops Technology that Allows Patients Control Over Their Healthcare Records 4
... SAN FRANCISCO, Oct. 26, 2011 Nektar Therapeutics (Nasdaq: ... third quarter ended September 30, 2011 on Wednesday, November 2, ... president and chief executive officer, will host a conference call ... (ET)/2:00 p.m. Pacific Time (PT). The press ...
... Galleon Pharmaceuticals, a leader in the pharmaceutical treatment of ... has elected Thomas J. Dietz, Ph.D., as the company,s ... Holdings, LLC, a diversified financial-holdings and services company.   ... then CEO and a director of Pacific Growth Equities, ...
Cached Medicine Technology:Nektar to Announce Financial Results for the Third Quarter of 2011 on Wednesday, November 2, 2011, After Close of U.S.-Based Financial Markets 2Thomas Dietz, Ph.D., Elected Chairman of Galleon Pharmaceuticals 2
(Date:3/26/2015)... San Diego (PRWEB) March 26, 2015 ... to advance health and wellness for the poor and ... the application period for its annual $1 million award, ... is excited to announce the 2015 round of our ... "We've seen and supported some incredibly creative and ambitious ...
(Date:3/26/2015)... Calif. (PRWEB) March 26, 2015 UC ... innovative research into the origins of schizophrenia: A Silvio ... one of only 15 such centers in the United ... $10 million grant from the National Institutes of Mental ... investigate the novel hypothesis that an origin of schizophrenia ...
(Date:3/26/2015)... Tampa, FL (PRWEB) March 26, 2015 Florida ... the Taking Action For Your Health campaign and live Dr. ... mall on Saturday, March 21st. More than a thousand people ... message of healthy living. , The world renowned cardiothoracic ... Action News anchor Linda Hurtado and a panel of experts ...
(Date:3/26/2015)... (PRWEB) March 26, 2015 Xarelto ... forward nationwide, with the issuance of new court ... and Louisiana. According to an Order dated March ... established for Xarelto injury claims in the U.S. ... allow plaintiffs to file cases directly in the ...
(Date:3/26/2015)... March 26, 2015 Building off ... continuing medical education, the Cardiometabolic Risk Summit ... at Tulane University are proud to announce ... The interdisciplinary program , which ultimately ... is designed for physicians, nurse practitioners, physician assistants, ...
Breaking Medicine News(10 mins):Health News:Applications Open for $1M Innovation Initiative Award from Alliance Healthcare Foundation 2Health News:UC Davis Receives $10 Million Grant to Establish Center to Study Schizophrenia 2Health News:UC Davis Receives $10 Million Grant to Establish Center to Study Schizophrenia 3Health News:UC Davis Receives $10 Million Grant to Establish Center to Study Schizophrenia 4Health News:Florida Hospital Welcome Dr. Oz to Tampa and Invites the Community to Attend Educational Seminars Hosted by Florida Hospital Physicians 2Health News:Florida Hospital Welcome Dr. Oz to Tampa and Invites the Community to Attend Educational Seminars Hosted by Florida Hospital Physicians 3Health News:Xarelto Lawsuits Move Forward Nationwide, With Issuance of New Court Docs in State, Federal Litigations 2Health News:Xarelto Lawsuits Move Forward Nationwide, With Issuance of New Court Docs in State, Federal Litigations 3Health News:Certified Culinary Medicine Specialist Program Jointly Launched by Goldring Center for Culinary Medicine at Tulane University and Cardiometabolic Risk Summit 2Health News:Certified Culinary Medicine Specialist Program Jointly Launched by Goldring Center for Culinary Medicine at Tulane University and Cardiometabolic Risk Summit 3
... conducted this study which was self funded. The sweetness ... of the sweetener. // The researchers questioned about 30 ... sweeteners and sweet substances. This was done to detect ... with each substance. Sugar was rated highest. Participants found ...
... with fish oil supplements in teenagers.,Durham County Council’s senior ... 25 teenagers who had been rated with moderate to ... omega-3 fish and omega-6 evening primrose oil over a ... students aged 12 to 15 also had a high ...
... Prime Minister, Shaukat Aziz has been urged by the Poultry ... the poultry industry//. The industry is under crisis over the ... flu scare and the earthquake that hit the country on ... President of the Lahore Chamber of Commerce and Industry (LCCI) ...
... developed at Leeds that will benefit at large in ... the next generation// of miniaturized computers. ,By suspending ... and Dr Yulong Ding have created ‘nanofluids’ which can ... In a central heating system, nanofluids could increase efficiency ...
... Court, would ensure that patients or their relatives would be ... demand. Until now, patients and family members have been facing ... doctor or hospital as they tend to treat it as ... it is their property and therefore refuse to give the ...
... jointly by University of California, Berkeley, and Chilean researchers says ... in drinking water are more likely to succumb to lung ... in their adult life. ,It was found that ... than normal if the child's mother also drank the arsenic-contaminated ...
Cached Medicine News:Health News:Sweet, Sweeter and Sweetest 2Health News:Poultry Industry Of Pakistan Stresses On Need Of Relief Package 2Health News:Arsenic in Drinking Water Predisposes Children To Lung Cancer in Later Life 2
Lyphochek Diabetes Control is a human whole blood based product used to monitor hemoglobin fractions associated with diabetes, including Hemoglobins A1, A1C, F and Total Glycated Hemoglobin....
Lyphochek Hemoglobin A2 Control is a human whole blood based product designed to monitor the performance of automated and manual procedures for the measurement of hemoglobin variants, including Hemog...
... Liquichek Hematology-16 Control is ... on most hematology analyzers ... 16 parameters and 3-part ... This trilevel control can ...
Liquichek Hematology Control (C) is an assayed hematology control for evaluating the performance of Coulter hematology instruments with complete CBC and VCS 5-part differential technology....
Medicine Products: